Pomalidomide-Containing Regimens (PCR) for the Treatment of Relapsed and Refractory Multiple Myeloma

被引：0
|
作者：
Jimenez-Zepeda, Victor H. [1 ]
Venner, Christopher P. [2 ]
Belch, Andrew [3 ]
Sandhu, Irwindeep [4 ]
Nikitina, Tatiana [2 ]
Hewitt, Joanne D. [5 ]
Duggan, Peter [6 ]
Neri, Paola [7 ]
Rashid-Kolvear, Fariborz [8 ]
Bahlis, Nizar J. [7 ]
机构：
[1] Univ Calgary, Div Hematol, Calgary, AB, Canada
[2] Univ Alberta, Cross Canc Inst, Edmonton, AB, Canada
[3] Cross Canc Inst, Edmonton, AB T6G 1Z2, Canada
[4] Univ Alberta, Dept Med, Div Hematol, Edmonton, AB, Canada
[5] Cross Canc Inst, Nursing, Edmonton, AB T6G 1Z2, Canada
[6] Tom Baker Canc Clin, Dept Med Oncol & Hematol, Calgary, AB, Canada
[7] Univ Calgary, Southern Alberta Canc Res Inst, Calgary, AB, Canada
[8] Calgary Lab Serv, Calgary, AB, Canada
来源：
BLOOD | 2015年 / 126卷 / 23期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：4
相关论文
共 50 条
  • [31] The efficacy and safety of triplet regimens based on pomalidomide and dexamethasone for treatment of relapsed/refractory multiple myeloma: a systematic review and meta-analysis
    Liao, K-Y
    Liu, Y.
    Xiong, H.
    Chen, X-M
    Zhang, X-W
    Huang, C-L
    EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES, 2022, 26 (21) : 8087 - 8097
  • [32] ClaPD (Clarithromycin, Pomalidomide, Dexamethasone) Therapy in Relapsed or Refractory Multiple Myeloma
    Mark, Tomer M.
    Boyer, Angelique
    Rossi, Adriana C.
    Shah, Manan
    Pearse, Roger N.
    Zafar, Faiza
    Pekle, Karen
    Tegnestam, Linda
    Sacris, Erlinda A.
    Greenberg, June
    Speaker, Stephanie
    Jayabalan, David
    Ely, Scott A.
    Coleman, Morton
    Chen-Kiang, Selina
    Niesvizky, Ruben
    BLOOD, 2012, 120 (21)
  • [33] Comparison of Debulking Regimens (EPOCH and DCEP) for the Treatment of Relapsed or Refractory Multiple Myeloma
    Kowalski, Andrew
    Coffey, David G.
    Diamond, Benjamin
    Hoffman, James E.
    Kaddoura, Marcella
    Lykon, Jill
    Maura, Francesco
    Rodriguez-Martinez, Yahirini
    Rosen, Suzan
    Shah, Faika
    Verducci, Dennis
    Landgren, Ola
    Kazandjian, Dickran
    BLOOD, 2024, 144 : 2389 - 2390
  • [34] Clarithromycin, pomalidomide, and dexamethasone (ClaPD) in relapsed or refractory multiple myeloma.
    Rossi, Adriana C.
    Mark, Tomer Martin
    Rodriguez, Melissa
    Shah, Manan
    Quinn, Ryann
    Pearse, Roger N.
    Zafar, Faiza
    Pekle, Karen
    Speaker, Stephanie
    Jayabalan, David
    Ely, Scott
    Coleman, Morton
    Chen-Kiang, Selina
    Niesvizky, Ruben
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [35] Selinexor, Pomalidomide, and Dexamethasone (SPd) in Patients with Relapsed or Refractory Multiple Myeloma
    Chen, Christine I.
    Bahlis, Nizar
    Gasparetto, Cristina
    Tuchman, Sascha A.
    Lipe, Brea C.
    Baljevic, Muhamed
    Kotb, Rami
    Sutherland, Heather J.
    Bensinger, William I.
    Sebag, Michael
    Leblanc, Richard
    Venner, Christopher P.
    Schiller, Gary J.
    Lentzsch, Suzanne
    Callander, Natalie Scott
    Sheehan, Heidi
    Chai, Yi
    Kai, Kazuharu
    Shah, Jatin
    Shacham, Sharon
    Kauffman, Michael G.
    White, Darrell J.
    BLOOD, 2019, 134
  • [36] Nivolumab, Pomalidomide, and Elotuzumab Combination Regimens for Treatment of Relapsed and Refractory Multiple Myeloma: Results from the Phase 3 CheckMate 602 Study
    Oriol, Albert
    Hajek, Roman
    Spicka, Ivan
    Sandhu, Irwindeep
    Cohen, Yael C.
    Gatt, Moshe E.
    Mariz, Jose
    Cavo, Michele
    Berdeja, Jesus
    Jin, Kexin
    Bar, Merav
    Das, Prianka
    La Motte-Mohs, Ross
    Wang, Yu
    Perumal, Deepak
    Costa, Luciano J.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 (10): : 703 - 714
  • [37] Elotuzumab in combination with pomalidomide, bortezomib, and dexamethasone in relapsed and refractory multiple myeloma
    Yee, Andrew J.
    Laubach, Jacob P.
    Campagnaro, Erica L.
    Lipe, Brea C.
    Nadeem, Omar
    Friedman, Robb S.
    Cole, Craig E.
    O'Donnell, Elizabeth K.
    Bianchi, Giada
    Branagan, Andrew R.
    Schlossman, Robert L.
    Shapiro, Samantha J.
    Harrington, Cynthia C.
    Burke, Jill N.
    Gammon, Marilyn T.
    Lively, Kathleen J.
    Reimonn, Cassandra A.
    Andrade, Danielle X.
    Redd, Robert
    Lohr, Jens G.
    Anderson, Kenneth C.
    Richardson, Paul G.
    Raje, Noopur S.
    BLOOD ADVANCES, 2025, 9 (05) : 1163 - 1170
  • [38] Pomalidomide and Dexamethasone Treatment for ≥ 1 Year in Renally Impaired Patients With Relapsed or Refractory Multiple Myeloma
    Weisel, Katja
    Dimopoulos, Meletios A.
    Cook, Mark
    Ramasamy, Karthik
    De La Rubia, Javier
    Ardizzoia, Antonio
    Krauth, Maria Theresa
    Jaccard, Arnaud
    Van de Donk, Niels
    Kueenburg, Elisabeth
    Di Micco, Antonia
    Rosettani, Barbara
    Atiba-Davies, Margaret
    Bacon, Pamela
    Sonneveld, Pieter
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 (10): : E284 - E285
  • [39] Daratumumab vs pomalidomide for the treatment of relapsed/refractory multiple myeloma: A cost-effectiveness analysis
    Gong, Cynthia L.
    Studdert, Ann L.
    Liedtke, Michaela
    AMERICAN JOURNAL OF HEMATOLOGY, 2019, 94 (03) : E68 - E70
  • [40] Pomalidomide-Based Regimens for Treatment of Relapsed and Relapsed/Refractory Multiple Myeloma: Systematic Review and Meta-analysis of Phase 2 and 3 Clinical Trials
    Mushtaq, Adeela
    Iftikhar, Ahmad
    Hassan, Hamza
    Lakhani, Midhat
    Sagar, Fnu
    Kamal, Ahmad
    Zahid, Umar
    Ali, Zeeshan
    Razzaq, Faryal
    Abu Zar, Muhammad
    Hassan, Syeda Fatima
    Safdar, Ahmad
    Raychaudhuri, Sreejata
    Anwer, Faiz
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 (07): : 447 - 461
12345